301 Carlson Parkway
Suite 210
Minneapolis, MN 55305
United States
(763) 496-5454
https://www.diamedica.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 18
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Dietrich John Pauls MBA | President, CEO & Director | 818.61k | N/A | 1971 |
Mr. Scott Kellen CPA | CFO & Corporate Secretary | 485.43k | N/A | 1965 |
Dr. Kirsten L. Gruis M.D., M.S. | Independent Consultant | 449.29k | N/A | 1973 |
Dr. Ambarish Shah Ph.D. | Chief Technology Officer | N/A | N/A | N/A |
Mr. Dominic R. Cundari | Chief Commercial Officer | N/A | N/A | 1951 |
Mr. David J. Wambeke | Chief Business Officer | N/A | N/A | 1984 |
Dr. Lorianne K. Masuoka M.D. | Chief Medical Officer | N/A | N/A | 1961 |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.